Nox1 is of considerable importance because of its involvement in a wide variety of pathologies. Activation of Nox1 induces generation of reactive oxygen species (ROS) and cell migration, events critical for the pathogenesis of cardiovascular disease, amyotropic lateral sclerosis, gastrointestinal disease, immunological disorders, and multiple forms of cancer [1-8]. In order to best determine how to treat Nox1-mediated disease, we must gain a better understanding of the mechanisms that control Nox1 activation. Within the last decade, many studies have found that protein phosphorylation and protein trafficking are critical regulatory mechanisms that control the activation of multiple Nox proteins. Yet, to date, no studies have characterized Nox1 phosphorylation or trafficking. We hypothesized that the activity of Nox1 is controlled by its phosphorylation at specific residues and by its sub-cellular localization; and that modifying Nox1 phosphorylation or localization will alter Nox1-dependent signaling. To test this hypothesis, we utilized both in vivo and in vitro approaches. We found that phosphorylation of Nox1 is significantly increased under pathological conditions in three in vivo models: (1) in atherosclerotic vs. normal aorta from monkey, (2) in neointimal vascular smooth muscle cells (VSMCs) vs. medial VSMCs from rat following aortic balloon injury, and (3) in ligated vs. normal carotid from mouse. Studies using mass spectroscopy, pharmacological inhibition, siRNA, and in vitro phosphorylation identify PKC-βI as a kinase that mediates Nox1 phosphorylation and subsequent ROS production and VSMC migration. Site-directed mutagenesis of predicted Nox1 phospho-residues revealed that cells expressing mutant Nox1 T429A have a significant decrease in TNF-α-stimulated ROS production, VSMC migration and Nox1 NADPH oxidase complex assembly compared to cells expressing wild-type Nox1. Isothermal calorimetry (ITC) revealed that a peptide containing the Activation Domain of NoxA1 (LEPMDFLGKAKVV) binds to phosphorylated Nox1 peptide (KLK-phos-T(429)- QKIYF) but not non-phosphorylated Nox1 peptide. These findings indicate that phosphorylation of Nox1 residue T429 by PKC-βI promotes TNF-α-induced Nox1 NADPH oxidase complex assembly, ROS production, and VSMC migration. Nox1 localization and trafficking studies reveal that Nox1 endocytosis is necessary for TNF-α-induced Nox1 ROS production; and that mutation of a Nox1 VLV motif inhibits Nox1 endocytosis and ROS production. These studies have provided new evidence that phosphorylation and sub-cellular localization are involved in the regulation of Nox1 ROS production and cell migration and offer new insights as to how Nox1 activity can be targeted for the purpose of treating Nox1-mediated diseases.

Development of an in vitro model for the early stages of cardiovascular disease is a current necessity. Cardiovascular disease is the leading cause of death in the United States and throughout the world. Oxidative stress and reactive oxygen species have been implicated in cardiovascular disease development. An in vitro model of these processes will improve our understanding of cardiovascular disease development and allow for the development of additional treatments. Atherosclerosis is an inflammatory disease and increased levels of H2O2 are associated with inflammation. The model focuses on H2O2-induced oxidative stress under static and shear conditions. Previous studies have documented increased O2.- and increased cytotoxicity in smooth muscle cells exposed to H2O2. Under static culture, endothelial cells exposed to H2O2, exhibited increased O2.- over basal levels via NOS and NAPDH oxidase pathways. Increased O2.- was attenuated by MnSOD adenoviral-mediated upregulation and endothelial cell exposure to Tiron. This suggests NOS and NADPH oxidase as sources of increased O2.- under H2O2-induced oxidative stress. Endothelial cell cytotoxicity was increased with H2O2 exposure. The increase in cytotoxicity was diminished upon exposure to Tiron or L-NAME. Under shear conditions (8.2 dynes/cm2), endothelial cells exposed to H2O2 exhibited increased O2.- compared to control via an L-NAME (specific inhibitor NOS) and Apocynin (NADPH oxidase inhibitor) inhibitable mechanism. This suggests NOS and NADPH oxidase as sources of increased O2.- under H2O2-induced oxidative stress. The increased O2.- was attenuated with MnSOD adenoviral-mediated upregulation and endothelial cell exposure to Tiron (an O2.-scavenger). Endothelial cell attachment under shear with exposure to H2O2 was improved with MnSOD adenoviral-mediated upregulation as observed by decreased loss of the endothelial cell monolayer compared with H2O2 exposed endothelial cells. Endothelial cells exposed to H2O2 exhibit increased O2.-, suggesting that H2O2-induced oxidative stress may be a reasonable model for atherosclerosis. NOS and NADPH oxidase co-inhibition under shear and static culture demonstrated that NOS and NADPH oxidase inhibition is non-additive under static culture, yet additive under shear. Co-inhibition results suggest a complex relationship between the two enzymes that requires additional experimentation to deconvolve.

Das Renin-Angiotensin-Aldosteron-System (RAAS) reguliert den Blutdruck sowie den Elektrolyt- und Wasserhaushalt. Das aktive Peptid, Angiotensin II (AngII), führt dabei zur Vasokonstriktion und in höheren Konzentrationen zu Bluthochdruck. Hypertensive Patienten haben ein erhöhtes Risiko an Krebs zu erkranken, vor allem an Nierenkrebs. Wir konnten bereits in vivo zeigen, dass AngII in der Lage ist, den Blutdruck zu steigern und dosisabhängig zu DNA-Schäden über den Angiotensin II Typ 1-Rezeptor (AT1R) führt. Ein stimuliertes RAAS kann ferner über die Aktivierung der NADPH-Oxidase, einer Hauptquelle der Generierung reaktiver Sauerstoffspezies (ROS) in der Zelle, zu oxidativem Stress führen. Zielsetzung dieser Arbeit war es zum einen, mit Hilfe von AT1a-Rezeptor-defizienten Mäusen in vivo zu prüfen, ob die Bildung von ROS, sowie die Bildung von DNA-Schäden in der Niere und im Herzen unabhängig von einem erhöhten Blutdruck auftreten. Zum anderen sollte, ebenfalls in vivo, untersucht werden, ob eine oder beide von zwei untersuchten Isoformen der NADPH-Oxidase (Nox) für die Auslösung oxidativen Stresses in der Niere verantwortlich ist. Zunächst wurden für den Versuch zur Überprüfung der Abhängigkeit AngII-induzierter DNA-Schäden vom Blutdruck männliche C57BL/6-Mäuse und AT1a-Knockout (KO)-Mäuse mit osmotischen Minipumpen ausgestattet, die AngII in einer Konzentrationen von 600 ng/kg min über einen Zeitraum von 28 Tagen abgaben. Zusätzlich wurde eine Gruppe von AngII-behandelten Wildtyp (WT)-Mäusen mit dem AT1-Rezeptor-Blocker Candesartan (Cand) behandelt. Während des Versuchszeitraumes fanden regelmäßige, nicht-invasive Blutdruckmessungen an den wachen Mäusen statt. In WT-Mäusen induzierte AngII Bluthochdruck, verursachte erhöhte Albumin-Level im Urin und führte zur Bildung von ROS in Niere und im Herzen. Außerdem traten in dieser Gruppe DNA-Schäden in Form von Einzel- und Doppelstrangbrüchen auf. All diese Reaktionen auf AngII konnten jedoch durch gleichzeitige Behandlung mit Cand verhindert werden. AT1a-KO-Mäuse hatten, verglichen mit WT-Kontrollmäusen, einen signifikant niedrigeren Blutdruck und normale Albumin-Level im Urin. In AT1a-KO-Mäusen, die mit AngII behandelt wurden, konnte kein Anstieg des systolischen Blutdrucks sowie kein Einfluss auf die Nierenfunktion gefunden werden. Jedoch führte AngII in dieser Gruppe zu einer Steigerung von ROS in der Niere und im Herzen. Zusätzlich wurden genomische Schäden, vor allem in Form von Doppelstrangbrüchen signifikant in dieser Gruppe induziert. Auch wenn AT1a-KO-Tiere, unabhängig von einer AngII-Infusion, keine eingeschränkte Nierenfunktion zeigten, so wiesen sie erhebliche histopathologische Schäden im Hinblick auf die Glomeruli und das Tubulussystem auf. Diese Art von Schäden deuten auf eine besondere Bedeutung des AT1aR im Hinblick auf die embryonale Entwicklung der Niere hin. Zusammenfassend beweisen die Ergebnisse dieses Experiments eindeutig, dass eine AngII-induzierte ROS-Produktion und die Induktion von DNA-Schäden unabhängig von einem erhöhten Blutdruck auftreten. Da in der AngII-behandelten AT1a-KO-Gruppe eine signifikant höhere Expression des AT1b-Rezeptors zu finden war und die Blockade von beiden Rezeptorsubtypen mit Cand zu einer Verhinderung der schädlichen Effekte durch AngII führte, scheint der AT1bR im Falle einer AT1aR-Defizienz für die Entstehung der Schäden zuständig zu sein. Ziel des zweiten Experimentes war es, den Beitrag der Nox2 und Nox4 zum oxidativen DNA-Schaden in vivo zu untersuchen. Hierfür wurden männliche C57BL/6-Mäuse und Nox2- oder Nox4-defiziente Mäuse mit osmotischen Minipumpen ausgestattet, die AngII in einer Konzentration von 600 ng/kg min über einen Zeitraum von 28 Tagen abgaben. Im WT-Stamm und in beiden Nox-defizienten Stämmen induzierte AngII Bluthochdruck, verursachte erhöhte Albumin-Level im Urin und führte zur Bildung von ROS in der Niere. Außerdem waren in allen AngII-behandelten Gruppen genomische Schäden, vor allem in Form von Doppelstrangbrüchen, erhöht. Auch in Abwesenheit von AngII wiesen Nox2- und Nox4-defiziente Mäuse mehr Doppelstrangbrüche im Vergleich zu WT-Kontrollmäusen auf. Interessanterweise kompensieren allerdings weder Nox2 noch Nox4 das Fehlen der jeweils anderen Isoform auf RNA-Basis. Aufgrund dieser Ergebnisse schließen wir, dass bislang keine Isoform alleine für die Generierung von oxidativen DNA-Schäden in der Niere verantwortlich gemacht werden kann und dass eine Beteiligung einer weiteren Nox-Isoform sehr wahrscheinlich ist. Möglicherweise könnten aber auch andere ROS-generierende Enzyme, wie Xanthinoxidase oder Stickoxidsynthase involviert sein. Da genomische Schäden in Nieren von Nox2- und Nox4-defizienten Mäusen in Abwesenheit von AngII gegenüber den Schäden in WT-Kontrollmäusen erhöht waren, könnten die beiden Isoformen auch eine schützende Funktion im Bereich von Nierenkrankheiten übernehmen. Da dies aber bislang nur für Nox4 beschrieben ist, ist es wahrscheinlicher, dass das Fehlen von einer der beiden Isoformen eher einen Einfluss auf die Embryonalentwicklung hat. Um dies jedoch abschließend zu klären wäre es sinnvoll mit induzierbaren Knockout-Modellen zu arbeiten, bei denen mögliche entwicklungsbedingte Effekte minimiert werden können. / The renin-angiotensin-aldosterone system (RAAS) regulates blood pressure, electrolyte metabolism and water balance. The reactive peptide, Angiotensin II (AngII), of the RAAS causes vasoconstriction and, in higher concentrations, increased blood pressure. Hypertensive patients have an increased risk to develop cancer, especially kidney cancer. We have shown in vivo, that AngII is capable to cause an elevation of blood pressure, as well as DNA damage dose-dependently via the AngII type 1 receptor (AT1R). A stimulated RAAS can further lead to oxidative stress by activating NADPH oxidases which are major enzymatic sources of reactive oxygen species (ROS) in the cell. On the one hand the aim of this work was to examine in vivo with the help of AT1aR-deficient mice whether the formation of ROS and DNA damage in the kidney and the heart occur independently of an increased blood pressure. On the other hand we wanted to investigate whether one or both of the two examined isoforms of the NADPH oxidase (Nox) is responsible for the triggering of oxidative stress in the kidney. For the purpose of the first experiment which examined the dependency of AngII-induced DNA damage on blood pressure, male C57BL/6-mice and AT1a-knockout (KO)-mice were equipped with osmotic minipumps, delivering AngII in a concentration of 600 ng/kg x min during 28 days. Additionally, wild-type (WT) mice were treated with the AT1R antagonist candesartan (cand). Over the whole time period, frequent non-invasive blood pressure measurements were taken. In WT mice, AngII induced hypertension, an elevated urinary albumin level and formation of ROS in kidney and heart. Furthermore, genomic damage, in form of single- and double strand breaks, was augmented in this group. All these responses to AngII could be attenuated by concurrent administration of candesartan. AT1a-deficient mice had lower basal systolic pressures than WT mice and comparable urinary albumin levels. In AT1a-deficient mice treated with AngII, systolic pressure was not increased, and no effect on renal function could be detected. However, AngII led to an increase of ROS in kidney and heart in this group. In addition, genomic damage, especially in form of double strand breaks was significantly induced. Although AT1a-KO-mice, independent of an AngII-infusion, showed no renal impairment they had significant histopathological changes in glomeruli and tubules. This points to a special importance of AT1aR with regard to the embryonic development of the kidney. In summary our results clearly demonstrate that AngII-induced ROS production and DNA damage is independent of blood pressure. Since we found a significantly higher expression of the AT1bR in the AngII-treated AT1aR-KO-group and since blocking of both subtypes with cand resulted in a complete prevention of adverse AngII effects, the receptor responsible for the mediation of these effects seems to be AT1bR. The aim of the second experiment was to examine the contribution of Nox2 and Nox4 to oxidative DNA damage in vivo. Therefore male C57BL/6-mice and Nox2- or Nox4-deficient mice were equipped with osmotic minipumps, delivering AngII in a concentration of 600 ng/kg × min during 28 days. In WT and in both strains of Nox-deficient mice, AngII induced hypertension, elevated urinary albumin levels and formation of ROS in the kidney. Furthermore, genomic damage, especially in form of double strand breaks were augmented in all of the AngII-treated groups. Also in the absence of AngII, Nox2- and Nox4-deficient mice exhibited a higher background of double strand breaks. Interestingly neither Nox2 nor Nox4 do not compensate for the deficiency of the other isoform on mRNA level. Due to these results we conclude that there is no isoform so far which is solely responsible for the generation of ROS in the kidney under AngII-treatment. Potentially there might also be a contribution of other enzymes like xanthine oxidase or nitric oxide synthase to the formation of ROS. Since genomic damage in kidneys of Nox2- and Nox4-deficient mice in the absence of AngII was higher as compared to the damages in WT control mice it might be that both isoforms could have a protective role in renal disease. But, since this is so far only described for Nox4 it is likely that the absence of one of the two isoforms rather has an influence on the embryonic development. To finally clarify this hypothesis it would be suggestive to work with inducible knockout mouse models where possible developmental effects can be minimized.

La prévalence de l'obésité est en constante augmentation dans les pays occidentaux, en raison d'une sédentarisation accompagnée d'une alimentation malsaine. L'obésité est souvent associée à une dysfonction endothéliale et à un risque athérogène élevé. Plusieurs observations cliniques ont montré que la modification du mode de vie, incluant la pratique régulière d'une activité physique et l'adoption d'un mode alimentaire sain, représente une stratégie efficace pour combattre l'obésité et ses complications cardiovasculaires. Cependant, de nombreux mécanismes précisant les effets thérapeutiques directs de l'exercice physique sur le risque athérogène lié à l'obésité sont encore largement inconnus. Le but principal de ce travail a donc été d'identifier, en utilisant un modèle de rat rendu obèse par un régime enrichi en graisse, les mécanismes athéro-protecteurs de l'exercice physique seul et/ou associé à une modification du régime alimentaire (du régime riche en graisse au régime standard). Nos résultats montrent que l'exercice physique, indépendamment de la diète utilisée, corrige la dysfonction endothéliale installée au cours de l'obésité. Cet effet bénéfique a été associé à une diminution du stress oxydatif au niveau vasculaire. En effet, nos résultats indiquent que l'exercice diminue l'activité de la NADPH oxydase au niveau aortique. De plus, nous montrons pour la première fois que l'exercice physique seul, indépendamment de la diète utilisée, est capable de moduler la translocation de la sous-unité de la NADPH oxydase p47phox (principal acteur dans l'activation de ce complexe enzymatique) vers la membrane. Nos résultats indiquent également que l'exercice physique, avec ou sans modification du régime, améliore la voie Akt/eNOS phosphorylée, suggérant une augmentation de la production du NO. Ainsi, l'exercice physique, même sans l'associer à un changement du mode alimentaire, peut être considéré comme une stratégie non-pharmacologique efficace pour le traitement du risque athérogène généré par l'obésité

Dans les organismes photosynthétiques, la ferrédoxine:NADP oxydoréductase (FNR) fournit le NADPH nécessaire à l'assimilation du CO2, mais elle réduit aussi la ferrédoxine (Fd) à partir du NADPH. La cyanobactérie Synechocystis sp. PCC6803 contient deux isoformes de FNR : une forme courte (FNRS, 34 kDa) et une forme longue (FNRL, 46 kDa) qui est liée au phycobilisome (PBS), un complexe collecteur de lumière. Nous avons purifié un sous-complexe du PBS qui contient la FNRL (FNRL-PC) et comparé les propriétés enzymatiques de FNRL-PC à FNRS. Par rapport à FNRS, FNRL-PC présente des affinités plus faible/forte pour le NADPH/la Fd, conformément aux prédictions des activités relatives des deux isoformes. La plupart des différences observées sont attribuées à l'encombrement stérique amené par la phycocyanine dans FNRL-PC. En conditions de turnover multiple, les deux isoformes catalysent de la même manière la réduction de NADP+ et de plus le transfert d'électrons (TE) depuis Fdred est limitant à force ionique élevée. Lors d'études in vivo, nous avons observé une augmentation de l'oxydation du NADPH par TE respiratoire ou cyclique chez un mutant ne contenant que la FNRS et chez le type sauvage à faible CO2. Les mesures ont montré clairement que FNRS est impliqué dans ce TE alternative et nous proposons que FNRS constitue le module déshydrogénase de NDH-1. La localisation de la FNR et/ou la présence de substrats semblent être essentiels dans les rôles respectifs des isoformes de FNR in vivo. Des études futures devraient nous donner une vue plus complète des processus de TE in vivo et clarifier le rôle du TE dépendant du NADPH et favorisé par FNRS dans la réduction du pool de PQ

Dans les organismes photosynthétiques, la ferrédoxine:NADP oxydoréductase (FNR) fournit le NADPH nécessaire à l'assimilation du CO2, mais elle réduit aussi la ferrédoxine (Fd) à partir du NADPH. La cyanobactérie Synechocystis sp. PCC6803 contient deux isoformes de FNR : une forme courte (FNRS, 34 kDa) et une forme longue (FNRL, 46 kDa) qui est liée au phycobilisome (PBS), un complexe collecteur de lumière. Nous avons purifié un sous-complexe du PBS qui contient la FNRL (FNRL-PC) et comparé les propriétés enzymatiques de FNRL-PC à FNRS. Par rapport à FNRS, FNRL-PC présente des affinités plus faible/forte pour le NADPH/la Fd, conformément aux prédictions des activités relatives des deux isoformes. La plupart des différences observées sont attribuées à l'encombrement stérique amené par la phycocyanine dans FNRL-PC. En conditions de turnover multiple, les deux isoformes catalysent de la même manière la réduction de NADP+ et de plus le transfert d'électrons (TE) depuis Fdred est limitant à force ionique élevée. Lors d'études in vivo, nous avons observé une augmentation de l'oxydation du NADPH par TE respiratoire ou cyclique chez un mutant ne contenant que la FNRS et chez le type sauvage à faible CO2. Les mesures ont montré clairement que FNRS est impliqué dans ce TE alternative et nous proposons que FNRS constitue le module déshydrogénase de NDH-1. La localisation de la FNR et/ou la présence de substrats semblent être essentiels dans les rôles respectifs des isoformes de FNR in vivo. Des études futures devraient nous donner une vue plus complète des processus de TE in vivo et clarifier le rôle du TE dépendant du NADPH et favorisé par FNRS dans la réduction du pool de PQ.

<p>Apoptosis is a form of programmed cellular "suicide" which is activated in response to a variety of pro-death stimuli. Apoptotic cell death is orderly and energy-dependent, and cellular constituents are packaged into membrane-bound vesicles for consumption by phagocytes. Toxic intracellular signals are never exposed to neighboring cells or to the extracellular environment, and a host inflammatory response does not occur. Apoptosis is executed by the coordinated activation of caspase family proteins. Caspase-2 is an apical protease in this family, and promotes cell death after receipt of cues from intracellular stressor signals. Caspase-2 helps to initiate apoptosis by responding to cellular death stimuli and signaling for downstream cytochrome c release and executioner caspase activation.</p><p> Several years ago our lab determined that Xenopus laevis oocyte death is partly controlled by the activation of caspase-2. In the setting of oocyte or egg extract nutrient depletion, caspase-2 was observed to be activated upstream of mitochondrial cytochrome c. In fact, caspase-2 is suppressed in response to the nutrient status of the oocyte: nutrient-replete oocytes with healthy pentose phosphate pathway flux and abundant NADPH production are able to inhibit caspase-2 via S135 phosphorylation catalyzed by calcium/calmodulin-dependent protein kinase II. Phosphorylation of caspase-2 at S135 is critical in preventing oocyte cell death, and a caspase-2 mutant unable to be phosphorylated loses its ability to respond to suppressive NADPH signals. </p><p> In this dissertation we examine the converse mechanism of metabolically-regulated caspase-2 activation in the Xenopus egg extract. We now show that caspase-2 phosphorylated at S135 binds the interactor 14-3-3 zeta, thus preventing caspase-2 dephosphorylation. Moreover, we determined that S135 dephosphorylation is catalyzed by protein phosphatase-1, which directly binds caspase-2. Although caspase-2 dephosphorylation is responsive to metabolism, neither PP1 activity nor binding is metabolically regulated. Rather, release of 14-3-3 zeta from caspase-2 is the point of metabolic control and allows for caspase-2 dephosphorylation. Accordingly, a caspase-2 mutant unable to bind 14-3-3 zeta is highly susceptible to activation. Although this mechanism was initially established in Xenopus, we now demonstrate similar control of murine caspase-2 by phosphorylation and 14-3-3 binding in mouse eggs. </p><p> In the second part of this dissertation we examine the paradigm of caspase-2 metabolic regulation in a mammalian somatic cell context. We observed that mammalian caspase-2 is a metabolically-regulated phosphoprotein in somatic cells, and that the site of regulation is caspase-2 S164. Phosphorylation at S164 appears to inhibit mammalian caspase-2 by preventing its induced proximity oligomerization, thus also preventing procaspase-2 autocatalytic processing. We further identify some of the molecular machinery involved in S164 phosphorylation and demonstrate conservation with the validated Xenopus regulators. Interestingly, we extend the findings of caspase-2 phosphorylation to a study of ovarian cancer, and show that caspase-2 S164 phosphorylation might be involved in determining cancer cell chemosensitivity. We further provide evidence that chemosensitivity can be modulated by the cellular metabolic status in a caspase-2-dependent manner. Thus, we have identified a novel phosphorylation site on mammalian caspase-2 in somatic cells, and are working further to understand the implications of caspase-2 signaling in the context of cancer cell responsiveness to chemotherapeutic treatments.</p> / Dissertation

Thesis (Ph.D.)--Virginia Commonwealth University, 2009. / Prepared for: Dept. of Physiology. Title from resource description page. Includes bibliographical references.

Thesis (doctoral)--Universität, Leipzig, 1999.

Myeloid-derived suppressor cells (MDSC) are a major component of the immune suppressive network that develops during cancer. MDSC down-regulate immune surveillance and antitumor immunity and facilitate tumor growth. The ability of MDSC to suppress T cell responses has been documented; however the mechanisms regulating this suppression remain to be understood. This work proposes a biological dichotomy of MDSC regulated by the tumor microenvironment. In peripheral lymphoid organs MDSC cause T-cell non-responsiveness that is antigen-specific. These MDSC have increased expression of NOX2, enabling them to produce large amounts of reactive oxygen species. Since the transcription factor STAT3 is substantially activated in MDSC, its potential role in upregulation of NOX2 expression was investigated. Over-expression of a constitutively active form of STAT3 increases expression of NOX2 subunits, whereas attenuation of STAT3 activity leads to decreased expression of NOX2. The significance of NOX2 in ROS generation is demonstrated in mice devoid of NOX2 function; NOX2- deficient MDSC are unable to inhibit antigen-induced activation of T cells. In contrast, MDSC within the tumor microenvironment have a diminished potential to generate ROS but acquire expression of arginase and inducible nitric oxide synthase, enzymes plicated in T cell non-responsiveness. Upregulation of these enzymes results in MDSC ability to inhibit lymphocyte response in absence of antigen presentation. The tumor microenvironment also promotes the differentiation of MDSC to tumor associated macrophages. Hypoxia is an exclusive feature to the tumor microenvironment and we investigated its involvement in the properties of MDSC at the tumor site. Exposure of spleen MDSC to hypoxia converts MDSC to non-specific suppressors and induces a preferential differentiation to macrophages. Stabilization of HIF-1!, a transcription factor activated by hypoxia, induces similar changes in MDCS as hypoxic exposure. Finally, ablation of HIF-1! prevents MDSC from acquiring factors that enable the suppression of T cells in absence of antigen. These findings help to expand our understanding of the biology of MDSC and suggest a regulatory pathway of myeloid cell function exclusive to the tumor microenvironment. They may also open new opportunities for therapeutic regulation as we now should take into consideration how systemic location affects the function of MDSC.